Bank of New York Mellon
MBRX icon

Bank of New York Mellon’s Moleculin Biotech MBRX Stock Holding History

Bank of New York Mellon’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31
Closed -$65K – 4155
2019
Q4 		$65K Hold
31
– – ﹤0.01% 4071
2019
Q3 		$78K Buy
31
+16
+107% +$41.3K ﹤0.01% 4062
2019
Q2 		$41K Hold
15
– – ﹤0.01% 4139
2019
Q1 		$27K Hold
15
– – ﹤0.01% 4140
2018
Q4 		$36K Buy
+15
New +$43.1K ﹤0.01% 4098

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $351M AUM 16.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon's MBRX Position: Q1 2020 in Review

Bank of New York Mellon sold out of Moleculin Biotech (MBRX) in Q1 2020, closing a stake of 31 shares — an estimated $65K sold.

Bank of New York Mellon first reported a position in MBRX in Q4 2018 and held it in 5 quarters. The position peaked at $78K in Q3 2019. 17 funds tracked by Wall St. Rank hold MBRX as of Q1 2020.

  • Bank of New York Mellon reported no remaining Moleculin Biotech position as of Q1 2020 after selling out during the quarter.
  • Bank of New York Mellon sold 31 Moleculin Biotech shares in Q1 2020, an estimated $65K.
  • Bank of New York Mellon first reported a position in Moleculin Biotech in Q4 2018 and held it in 5 quarters.
  • Bank of New York Mellon's Moleculin Biotech position peaked at $78K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2020.

Based on Bank of New York Mellon's 13F filing for Q1 2020, filed 6 May 2020.